← Back to patent-cliff list
拉米夫定
Tier C — Watch / tradeLamivudine
葛兰素史克
Originator
1995
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：RT
Brand：益平维、贺普丁、Zefix、Zeffix、Epivir
Indications (approved)：乙型肝炎、慢性乙型肝炎、HIV感染
Regional status
US
批准上市
1995-11-17
EU
批准上市
1996-08-08
China
批准上市
1999-03-08
Japan
批准上市
1997-02-14
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lamivudine?
Approved indications include: 乙型肝炎, 慢性乙型肝炎, HIV感染.
When does the Lamivudine patent expire?
No public expiry year is available for Lamivudine yet; this page updates once verified.
How do I get a quote for Lamivudine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25